FDA Inspection 1321426 — Zhongjun Xia, MD
The FDA completed an inspection of Zhongjun Xia, MD on May 22, 2026 in Guangzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 22, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Guangzhou (China)
Additional Details
Clinical Investigator (CI)